- call +1-201-465-4211
- email sales@mrinsights.biz
Cell-Free DNA are fragments of DNA which circulate in the blood fluid and can be utilized as valuable biomarkers. It is a new technology in which small quantity of liquid sample (saliva, urine, or blood) from the patient is collected to examine the freely flowing DNA. Cell-Free DNA (cfDNA) is a noninvasive screening test used to help detect graft rejection, identify mutations in cancer patients and detect various chromosomal abnormalities in the fetus, to know the gender of the fetus. The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology, transplantation and infectious diseases.
Scope of the Report:
This report studies the Cell-Free DNA (cfDNA) Testing market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cell-Free DNA (cfDNA) Testing market by product type and applications/end industries.
Increased incidences of diseases like chromosomal abnormalities due to increasing maternal age, changing lifestyle, unhealthy diet habits and rising prevalence of cancer, also in addition to it increasing healthcare expenditure, and rising healthcare awareness are the reasons driving the cell-free DNA market.
The global Cell-Free DNA (cfDNA) Testing market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cell-Free DNA (cfDNA) Testing.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Agilent Technology
Allenex
Biocept
Biodesix
CareDx
Guardant Health
Illumania
Invited
Natera
Quest Diagnostics
Roche Holdings
Sequenom
Trovagene
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Donor-Derived Cell-Free DNA (DdcfDNA)
Circulating Cell-Free Tumor DNA (CtDNA)
Cell-Free Fetal DNA (NIPT)
Market Segment by Applications, can be divided into
Hospital
Ambulatory Surgical Centers
Cancer Research Institutes
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Cell-Free DNA (cfDNA) Testing Market Overview
1.1 Product Overview and Scope of Cell-Free DNA (cfDNA) Testing
1.2 Classification of Cell-Free DNA (cfDNA) Testing by Types
1.2.1 Global Cell-Free DNA (cfDNA) Testing Revenue Comparison by Types (2017-2023)
1.2.2 Global Cell-Free DNA (cfDNA) Testing Revenue Market Share by Types in 2017
1.2.3 Donor-Derived Cell-Free DNA (DdcfDNA)
1.2.4 Circulating Cell-Free Tumor DNA (CtDNA)
1.2.5 Cell-Free Fetal DNA (NIPT)
1.3 Global Cell-Free DNA (cfDNA) Testing Market by Application
1.3.1 Global Cell-Free DNA (cfDNA) Testing Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital
1.3.3 Ambulatory Surgical Centers
1.3.4 Cancer Research Institutes
1.4 Global Cell-Free DNA (cfDNA) Testing Market by Regions
1.4.1 Global Cell-Free DNA (cfDNA) Testing Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Cell-Free DNA (cfDNA) Testing Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Cell-Free DNA (cfDNA) Testing Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Cell-Free DNA (cfDNA) Testing Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Cell-Free DNA (cfDNA) Testing Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Cell-Free DNA (cfDNA) Testing Status and Prospect (2013-2023)
1.5 Global Market Size of Cell-Free DNA (cfDNA) Testing (2013-2023)
2 Manufacturers Profiles
2.1 Agilent Technology
2.1.1 Business Overview
2.1.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Agilent Technology Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.2 Allenex
2.2.1 Business Overview
2.2.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Allenex Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.3 Biocept
2.3.1 Business Overview
2.3.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Biocept Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.4 Biodesix
2.4.1 Business Overview
2.4.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biodesix Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.5 CareDx
2.5.1 Business Overview
2.5.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 CareDx Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.6 Guardant Health
2.6.1 Business Overview
2.6.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Guardant Health Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.7 Illumania
2.7.1 Business Overview
2.7.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Illumania Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.8 Invited
2.8.1 Business Overview
2.8.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Invited Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.9 Natera
2.9.1 Business Overview
2.9.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Natera Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.10 Quest Diagnostics
2.10.1 Business Overview
2.10.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Quest Diagnostics Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.11 Roche Holdings
2.11.1 Business Overview
2.11.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Roche Holdings Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.12 Sequenom
2.12.1 Business Overview
2.12.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Sequenom Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
2.13 Trovagene
2.13.1 Business Overview
2.13.2 Cell-Free DNA (cfDNA) Testing Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Trovagene Cell-Free DNA (cfDNA) Testing Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cell-Free DNA (cfDNA) Testing Market Competition, by Players
3.1 Global Cell-Free DNA (cfDNA) Testing Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Cell-Free DNA (cfDNA) Testing Players Market Share
3.2.2 Top 10 Cell-Free DNA (cfDNA) Testing Players Market Share
3.3 Market Competition Trend
4 Global Cell-Free DNA (cfDNA) Testing Market Size by Regions
4.1 Global Cell-Free DNA (cfDNA) Testing Revenue and Market Share by Regions
4.2 North America Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
4.3 Europe Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
4.5 South America Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
5 North America Cell-Free DNA (cfDNA) Testing Revenue by Countries
5.1 North America Cell-Free DNA (cfDNA) Testing Revenue by Countries (2013-2018)
5.2 USA Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
5.3 Canada Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
5.4 Mexico Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
6 Europe Cell-Free DNA (cfDNA) Testing Revenue by Countries
6.1 Europe Cell-Free DNA (cfDNA) Testing Revenue by Countries (2013-2018)
6.2 Germany Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
6.3 UK Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
6.4 France Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
6.5 Russia Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
6.6 Italy Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Cell-Free DNA (cfDNA) Testing Revenue by Countries
7.1 Asia-Pacific Cell-Free DNA (cfDNA) Testing Revenue by Countries (2013-2018)
7.2 China Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
7.3 Japan Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
7.4 Korea Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
7.5 India Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
8 South America Cell-Free DNA (cfDNA) Testing Revenue by Countries
8.1 South America Cell-Free DNA (cfDNA) Testing Revenue by Countries (2013-2018)
8.2 Brazil Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
8.3 Argentina Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
8.4 Colombia Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Cell-Free DNA (cfDNA) Testing by Countries
9.1 Middle East and Africa Cell-Free DNA (cfDNA) Testing Revenue by Countries (2013-2018)
9.2 Saudi Arabia Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
9.3 UAE Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
9.4 Egypt Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
9.5 Nigeria Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
9.6 South Africa Cell-Free DNA (cfDNA) Testing Revenue and Growth Rate (2013-2018)
10 Global Cell-Free DNA (cfDNA) Testing Market Segment by Type
10.1 Global Cell-Free DNA (cfDNA) Testing Revenue and Market Share by Type (2013-2018)
10.2 Global Cell-Free DNA (cfDNA) Testing Market Forecast by Type (2018-2023)
10.3 Donor-Derived Cell-Free DNA (DdcfDNA) Revenue Growth Rate (2013-2023)
10.4 Circulating Cell-Free Tumor DNA (CtDNA) Revenue Growth Rate (2013-2023)
10.5 Cell-Free Fetal DNA (NIPT) Revenue Growth Rate (2013-2023)
11 Global Cell-Free DNA (cfDNA) Testing Market Segment by Application
11.1 Global Cell-Free DNA (cfDNA) Testing Revenue Market Share by Application (2013-2018)
11.2 Cell-Free DNA (cfDNA) Testing Market Forecast by Application (2018-2023)
11.3 Hospital Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.5 Cancer Research Institutes Revenue Growth (2013-2018)
12 Global Cell-Free DNA (cfDNA) Testing Market Size Forecast (2018-2023)
12.1 Global Cell-Free DNA (cfDNA) Testing Market Size Forecast (2018-2023)
12.2 Global Cell-Free DNA (cfDNA) Testing Market Forecast by Regions (2018-2023)
12.3 North America Cell-Free DNA (cfDNA) Testing Revenue Market Forecast (2018-2023)
12.4 Europe Cell-Free DNA (cfDNA) Testing Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Cell-Free DNA (cfDNA) Testing Revenue Market Forecast (2018-2023)
12.6 South America Cell-Free DNA (cfDNA) Testing Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Cell-Free DNA (cfDNA) Testing Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Cell-Free DNA (cfDNA) Testing Picture
Table Product Specifications of Cell-Free DNA (cfDNA) Testing
Table Global Cell-Free DNA (cfDNA) Testing and Revenue (Million U
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
